Search Results
Feb 10, 2026, 09:00 ET DEVONIAN REPORTS POSITIVE RESULTS IN PULMONARY FIBROSIS STUDY
of human idiopathic pulmonary fibrosis.Thykamine™ was administered orally at doses of 0.05, 0.1, 0.25, 0.5, and 1 mg/kg, and benchmarked against pirfenidone dosed at 220 mg/kg. Over a 21-day period, animals were monitored for body weight and survival, followed by comprehensive lung assessment. Fibrotic
More news about: Devonian Health Group Inc.
Feb 10, 2026, 09:00 ET BANG ENERGY LAUNCHES LIME POP DROP
from outside the traditional energy space and tapping into the playful side of lifestyle energy. With its neon-green aesthetic, punchy lime profile, 300mg of caffeine and zero sugar, Lime Pop Drop brings a fresh jolt of excitement to the category and invites fans to step fully into the limelight.Lucky
More news about: Bang Energy
Feb 10, 2026, 08:30 ET Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market
submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for upadacitinib (RINVOQ®; 15 mg, once daily) for the treatment of adult and adolescent patients living with non-segmental vitiligo (NSV). The regulatory submissions to the FDA and EMA
More news about: Market News Updates
Feb 10, 2026, 08:00 ET Vanscoy Rare Pharmacy Selected as Exclusive Distribution Pharmacy for Redemplo® (plozasiran) for adults with Familial Chylomicronemia Syndrome (FCS)
(FCS)Familial chylomicronemia syndrome (FCS) is a severe and rare disease leading to extremely high triglyceride (TG) levels, typically over 880 mg/dl. Such severe elevations can lead to various signs and symptoms including acute and potentially fatal pancreatitis, chronic abdominal pain, diabetes,
More news about: Vanscoy Rare Pharmacy
Feb 09, 2026, 09:07 ET Innocan Pharma Announces LPT-CBD demonstrates Pain Relief over Placebo-Results from a randomized blinded clinical study in Dogs
naturally occurring osteoarthritis received two subcutaneous injections in a randomized, blinded, crossover design: synthetic CBD in liposomes (LPT-CBD) 7 mg/kg and placebo (empty liposomes of identical amount and lipid composition) administered four weeks apart. Throughout the study, serial blood sampling
More news about: Innocan Pharma Corporation
Feb 09, 2026, 09:07 ET Innocan Pharma Announces LPT-CBD demonstrates Pain Relief over Placebo-Results from a randomized blinded clinical study in Dogs
naturally occurring osteoarthritis received two subcutaneous injections in a randomized, blinded, crossover design: synthetic CBD in liposomes (LPT-CBD) 7 mg/kg and placebo (empty liposomes of identical amount and lipid composition) administered four weeks apart. Throughout the study, serial blood sampling
More news about: Innocan Pharma Corporation
Feb 09, 2026, 09:01 ET REIGN Total Body Fuel Launches Bold New Watermelon Sour Gummy Flavor and Congratulates DeMarcus Lawrence on His Big Win
paired with REIGN's functional energy formula, bringing together taste, intensity, and purpose in every can.Watermelon Sour Gummy packs 300 mg of natural caffeine, BCAAs, and zero sugar to fuel intense workouts and active lifestyles. The new flavor delivers a mouth-puckering punch of watermelon
More news about: REIGN Total Body Fuel
Feb 09, 2026, 08:30 ET SQ Innovation's Lasix® ONYU Now Available for Order Through Major U.S. Pharmaceutical Distributors
The pharmaceutical component of Lasix ONYU is a novel, high-concentration formulation of the diuretic furosemide, at 30 mg/mL. It comes in a pre-filled glass cartridge containing 80 mg of furosemide in 2.67 mL. The Lasix ONYU Infusor consists of two main parts: the Reusable Unit and the Disposable Unit.
More news about: SQ Innovation
Feb 09, 2026, 01:07 ET BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China
that have significant clinical value. Under this Procedure, the assessment period is expected to be shortened.If approved, the SC-AI of 500 mg (two 250 mg injections) could be used to administer a once-weekly dose at home from the initiation of treatment, as an alternative to the current IV administration
More news about: BioArctic
Feb 09, 2026, 01:04 ET BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China
that have significant clinical value. Under this Procedure, the assessment period is expected to be shortened.If approved, the SC-AI of 500 mg (two 250 mg injections) could be used to administer a once-weekly dose at home from the initiation of treatment, as an alternative to the current IV administration
More news about: BioArctic
Feb 06, 2026, 09:08 ET Novo Nordisk takes the field at the big game, putting Wegovy® pill in consumers' hands
environment.2,6What is Wegovy®? Wegovy® (semaglutide) injection 1.7 mg or 2.4 mg and Wegovy® (semaglutide) tablets 25 mg are prescription medicines used with a reduced calorie diet and increased physical activity to: reduce
More news about: NOVO NORDISK INC.
Feb 06, 2026, 06:59 ET Aucta Pharmaceuticals, Inc. ("Aucta Pharmaceuticals") prepares for the launch of PYQUVI™ (deflazacort) oral suspension, the first of a new branded-generic rare disease product line
January launch of PYQUVI oral suspension 22.75 mg/mL. PYQUVI, a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older, is bioequivalent to Emflaza® (deflazacort) oral suspension 22.75 mg/mL. PYQUVI will be available exclusively through
More news about: Aucta Pharmaceuticals, Inc.
Feb 05, 2026, 10:10 ET Mexico's Vehicles in Operation Reach Record 36.1 Million at Year-End 2025, Reports IDF
survival of older vehicles on the road."The Chinese Makes Reality CheckThe report also clarified the impact of Chinese brands such as MG, BYD and Geely. While capturing high new-sale shares, their penetration in the total Mexico vehicle parc is still in the early stages:Light
More news about: IDF - Integrate Data Facts LLC
Feb 05, 2026, 10:10 ET Frota Circulante no México Atinge Recorde de 36,1 Milhões de Unidades ao Final de 2025, Revela IDF
respectivamente. A Realidade das Marcas de Origem Chinesa no Parque Circulante O relatório traz clareza sobre o impacto das marcas chinesas (como MG, BAIC, BYD, Chirey e Geely). Embora tenham atingido participação de dois dígitos nas vendas de novos, sua penetração na frota circulante total ainda é
More news about: IDF - Integrate Data Facts LLC
Feb 05, 2026, 10:10 ET El Parque Vehicular en México Alcanza Récord de 36.1 Millones de Unidades al Cierre de 2025, Reporta IDF
total. Marcas de origen chino: avance gradual dentro del parque automotor El reporte clarifica el impacto de las marcas de origen chino (como MG, BAIC, BYD, y Geely). Si bien han capturado cuotas de doble dígito en ventas anuales, su penetración en el parque vehicular total está en una etapa temprana:
More news about: IDF - Integrate Data Facts LLC
Feb 05, 2026, 09:35 ET $207B Market Shift: The Race for Fast Track Approval in Oncology
cancer following progression on CDK4/6 inhibitor treatment. The designation was supported by clinical data from the ReDiscover trial with 600mg BID fasted and 400mg BID fed doses showing comparable exposures across all PIK3CA mutations."This Breakthrough Therapy designation underscores the FDA's
More news about: USA News Group
Feb 05, 2026, 08:00 ET Insilico Medicine Nominates ISM5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate, for the Treatment of Multiple Inflammatory and Metabolism Indications
Interleukin-1β (IL-1β), a potent pro-inflammatory cytokine as a master regulator of the inflammatory response. Notably, even at the lowest tested dose of 0.3 mg/kg, IL-1β levels were nearly halved compared to the vehicle control group. This was followed by a steep, progressive reduction at higher dose levels, highlighting
More news about: Insilico Medicine
Feb 04, 2026, 19:50 ET New Published Case Series Explores Umbilical Cord Tissue Allografts in Plantar Fascia Care
three months of conservative therapy prior to allograft applicationIntervention: Single ultrasound-guided application of 2 cc of 150 mg/mL Wharton's jelly connective tissue allograft into areas of confirmed degenerationOutcomes Measured: NPRS, WOMAC, and Quality-of-Life
More news about: Regenative Labs
Feb 04, 2026, 12:51 ET Lupin Launches Topiramate Extended-Release Capsules in the United States
500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the launch of Topiramate Extended-Release Capsules, 25 mg, 50 mg, 100 mg, and 200 mg, in the United States, following the approval for its Abbreviated New Drug Application (ANDA) from the U.S. FDA.
More news about: Lupin Inc.
Feb 04, 2026, 09:37 ET VPT Expands NewSpace VSC Series with High-Efficiency Point of Load DC-DC Converter
Earth orbits (LEO), and NASA Class D missions where the balance of cost and guaranteed performance is critical. This series is radiation tested to 42 MeV/mg/cm² with no destructive SEE events (SEGR, SEB, SEL) and tested to 40 krad(Si), guaranteed to 30 krad(Si), for TID in accordance with VPT's in–house radiation
More news about: VPT, Inc.
Feb 04, 2026, 09:37 ET VPT Expands NewSpace VSC Series with High-Efficiency Point of Load DC-DC Converter
Earth orbits (LEO), and NASA Class D missions where the balance of cost and guaranteed performance is critical. This series is radiation tested to 42 MeV/mg/cm² with no destructive SEE events (SEGR, SEB, SEL) and tested to 40 krad(Si), guaranteed to 30 krad(Si), for TID in accordance with VPT's in–house radiation
More news about: VPT, Inc.
Feb 04, 2026, 07:00 ET Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026
levels tested were selected to advance into the Phase 3 program. The PEAK and PINNACLE Phase 3 studies are actively enrolling MESI subjects at the 5 mg and 10 mg dose levels versus sham.About Kodiak Sciences Inc.Kodiak Sciences (Nasdaq: KOD) is a precommercial retina focused biotechnology
More news about: Kodiak Sciences Inc.
Feb 04, 2026, 05:02 ET Foresee Pharmaceuticals Receives the Fourth Positive Recommendation from the DSMB to Continue the Casppian Ph3 Study, for Central Precocious Puberty (CPP)
evaluating the efficacy, safety, and pharmacokinetics of leuprolide (FP-001) 42 mg controlled-release in patients with central (Gonadotropin-Dependent) precocious puberty (CPP). Foresee's leuprolide injectable emulsion, 42 mg (marketed under the brand name CAMCEVI®), is currently approved
More news about: Foresee Pharmaceuticals Co., Ltd.
Feb 03, 2026, 16:11 ET Match Group Announces Fourth Quarter and Full-Year Results
Archer®, Upward®, YuzuTM, Salams®, HERTM, and other smaller brands.Match Group Asia ("MG Asia") consists of the world-wide activity of the brands Pairs® and Azar®.Direct Revenue is revenue that is
More news about: Match Group
Feb 03, 2026, 08:54 ET SYNEVIT® Supports Heart Valve Awareness Day with Bioavailable Calcium powder 1200mg
supply also goes toward things like blood clotting and heart rhythm. The medical site adds that adults need at least 1,000 mg of daily calcium intake and that rises to 1,200 mg with age.This is where CALCEED® can give health-conscious individuals an advantage."It all comes down to bioavailability,"
More news about: Synevit